PT-141 (Bremelanotide / Vyleesi)

Evidence: ★★★★☆ · Status: FDA Approved, Not Approved

In plain English

Works in the brain's desire centre rather than on plumbing — FDA-approved for low sexual desire in premenopausal women, used off-label by men.

How it works

α-MSH-derived peptide activating central melanocortin receptors MC3R/MC4R in brain desire/reward circuits — acting on libido centrally, unlike PDE-5 drugs (which act on blood flow).

Molecular target & official sources

MC4R melanocortin 4 receptor (NCBI Gene) · Bremelanotide (PubChem CID 9941379)

Protocol

~1.75 mg subcutaneous before activity.

Watch out

Nausea, transient BP rise, temporary skin darkening.

Bottom line

The only centrally-acting approved libido drug.

Helps with: Hormones & Testosterone · Sexual Health

Stacks with

Shares a pathway — often paired with: Setmelanotide (Imcivree), KPV, Melanotan II.

Availability & where to buy

Not widely approved. Not approved for general sale in most markets (Singapore included). Grey-market only — dose, purity and legality uncertain.

How it works: the Melanocortin pathway →

Used in these protocols

• Low Libido

Compare PT-141 (Bremelanotide / Vyleesi)

• PT-141 (Bremelanotide / Vyleesi) vs Testosterone (TRT)
• PT-141 (Bremelanotide / Vyleesi) vs Finasteride / Dutasteride
• PT-141 (Bremelanotide / Vyleesi) vs PDE-5 Inhibitors (Sildenafil / Tadalafil)
• PT-141 (Bremelanotide / Vyleesi) vs Anastrozole / Exemestane (Aromatase Inhibitors)
• PT-141 (Bremelanotide / Vyleesi) vs Tongkat Ali (Eurycoma longifolia)
• PT-141 (Bremelanotide / Vyleesi) vs Nandrolone (Deca-Durabolin)
• PT-141 (Bremelanotide / Vyleesi) vs Melanotan II